[Jackie07]

Hi Rosemary,

Hystersisters http://www.hystersisters.com/vb2/ has a forum for uterine cancer patients.

You might be able to find more information by searching 'endometrial cancer' such as this one: http://www.eyesontheprize.org/

Having surgery first runs the risks of 'stirring up' the cancer due to angiogenesis. Having chemo first also has the advantage of knowing whether or not certain chemo combo is effective. I think the decision needs to be made between you and your doctors. I'd strongly urge you to seek a 2nd opinon (from doctors of reputable institutions - not from patients like us.)

Below is an abstract located from PubMed about Sarcoma- not sure if it applies to uterine sarcomas:

Clin Cancer Res. 2010 Jan 15;16(2):530-40. Epub 2010 Jan 12.
NVP-BEZ235 as a new therapeutic option for sarcomas.

Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, GarcÃ*a-EcheverrÃ*a C, Mercuri M, Picci P, Scotlandi K.
Source

Laboratorio di Ricerca Oncologica, Istituto Ortopedico Rizzoli, Bologna, Italy.

Abstract

PURPOSE:

To evaluate the in vitro and in vivo effects of NVP-BEZ235, a dual pan-phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor in the three most common musculoskeletal tumors (osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma).
EXPERIMENTAL DESIGN:

Antiproliferative activity as well as the effects on migration and metastasis were evaluated in a panel of osteosarcoma, Ewing's sarcoma, as well as rhabdomyosarcoma cell lines. Moreover, simultaneous and sequential treatments were done in association with two of the most important conventional drugs in the treatment of sarcoma, doxorubicin and vincristine.
RESULTS:

NVPBEZ235 effectively blocked the pathway in in vitro and in vivo settings. Under the experimental conditions tested, the compound induced disease stasis, by arresting cells in G(1) phase of cell cycle, without remarkable effects on apoptosis. As a consequence, to obtain the maximum exploitation of its therapeutic potential, NVP-BEZ235 has been evaluated in combination with conventional cytotoxic agents, thus showing promising efficacy with either doxorubicin and vincristine. Inhibition of the phosphoinositide 3-kinase/mammalian target of rapamycin pathway increased activation of extracellular signal-regulated kinase 1/2, likely due to the presence of autocrine circuits shifting growth factor signaling toward the mitogen-activated protein kinase pathway. This supports the combined use of NVP-BEZ235 with other small signaling inhibitors. Here, we showed synergistic effects when the compound was associated with a anti-insulin-like growth factor-I receptor tyrosine kinase inhibitor. NVP-BEZ235 also inhibited cell migration and metastasis. Combination with vincristine further potentiated the antimetastatic effects.
CONCLUSIONS:

NVP-BEZ235 displays the features to be considered for sarcoma therapy to potentiate the activity of other anticancer agents. The drug is currently undergoing phase I/II clinical trials in advanced cancer patients.